hVIVO Reports Record Revenue and Strategic Expansion with Key Acquisitions

hVIVO Delivers Knockout Year: Record Revenue, Strategic Acquisitions, and a Bold Vision for 2028

If clinical trials were a boxing match, hVIVO just scored a technical knockout in 2024. The London-listed contract research organisation (CRO) has posted its strongest financial performance to date while executing a textbook expansion playbook. Let’s unpack what’s driving this growth – and why investors should be paying attention.

Financial Fireworks: More Cash, Higher Margins, Sustainable Growth

The numbers tell a compelling story:

• Revenue: £62.7 million (+11.9% YoY) – their third consecutive year of double-digit growth
• EBITDA: £16.4 million (+25.9% YoY) with margins expanding to 26.2%
• Cash pile: £44.2 million (up from £37m) with zero debt – a war chest for strategic moves
• Order book: £67 million (post-delivery of £62.7m in contracts) with 70% of 2025’s £73m guidance already secured

What’s particularly interesting is how they’ve achieved this. The 25.9% EBITDA jump outpaced revenue growth significantly – a clear sign of operational leverage kicking in. CEO Dr Yamin ‘Mo’ Khan attributes this to:

“Expedited project delivery and smart utilisation of our new Canary Wharf facility, which was partly client-funded. We’re running a tighter ship while scaling up.”

Operational Wins: Beyond the COVID Bump

While some pandemic-era darlings are struggling, hVIVO’s diversified model continues to shine:

Challenge Trial Dominance

• Completed 9 challenge trials across 7 pathogens including world-first Flu B trial
• £11.5m RSV contract with top-tier pharma client
• Pioneering work on human metapneumovirus (hMPV) models

New Revenue Streams Biting

• hLAB lab services proposals up 99% YoY
• Clinical site services recruited 817 participants in 43 days – their largest field trial to date
• FluCamp recruitment costs fell despite record volunteer numbers

The real kicker? Their new 50-bed Canary Wharf facility isn’t just a vanity project. This CL-3 certified site (think: handling nasty pathogens safely) enables concurrent trials and complex studies that were previously impossible. It’s like upgrading from a pop-up clinic to a biomedical fortress.

Strategic Chess Moves: Acquiring Growth Engines

Post-period acquisitions show hVIVO playing 4D chess:

1. CRS Clinical Research Units (€10m)

• Adds 120 beds across Mannheim and Kiel
• Opens German market access – crucial post-Brexit
• Expected earnings accretive by 2026

2. Cryostore (£3.2m)

• Biostorage business with 2-15 year client contracts
• “Ancillary but sticky” revenue stream as Khan puts it
• Immediately earnings-enhancing

These aren’t random deals. CRS brings Phase I-II capabilities complementing hVIVO’s challenge trial specialism. Cryostore slots neatly into hLAB’s sample analysis services. It’s vertical integration meets geographic expansion.

Future Horizons: The £100m Roadmap

The 2028 ambition isn’t just pie-in-the-sky:

• 2025 Guidance: £73m revenue (H2-weighted due to acquisition timing)
• Pipeline: Active discussions on hMPV trials and ILiAD’s Phase III whooping cough study (potentially their largest HCT ever)
• Regulatory Tailwinds: FDA engagement on HCTs for pivotal trials – a game-changer for industry adoption

Chair Cathal Friel’s impending departure (after transforming two loss-makers into this cash machine) adds a note of transition. But with 70% of 2025 revenue already contracted and £44m cash available, this isn’t a ship that needs steadying – it’s one ready to accelerate.

The Bottom Line: Why This Matters

hVIVO is executing a rare trifecta in biotech services:

1. Specialist leadership: Maintaining world #1 position in challenge trials
2. Intelligent diversification: Adding adjacent services with high margin potential
3. Financial discipline: Growing EBITDA faster than revenue while paying dividends

As Big Pharma seeks faster, cheaper routes to drug approval, hVIVO’s model becomes increasingly compelling. With the shares still flying under many radars (they’re barely covered by analysts), this could be one of AIM’s best-kept secrets – but probably not for long.

Disclosure: The author does not hold positions in HVO at time of writing. Always do your own research.